护地板细胞淋巴瘤老年患者的治疗结果:一个多中心的真实世界数据
Ebru Kilic Gunes1, Filiz Yavasoglu2, Selin Kucukyurt3
1Department of Hematology, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey.
概括
优化对老年地细胞淋巴瘤 (MCL) 患者的治疗仍然具有挑战性. 这项研究确定了影响生存的关键因素,表明向治疗和维护策略可能会改善这一群体的结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 膜细胞淋巴瘤 (MCL) 是一种罕见的非霍奇金淋巴瘤 (NHL) 亚型.
- 对于老年患者 (≥65岁) 缺乏标准化治疗.
- 优化老年MCL患者的治疗是一个重大的临床挑战.
研究的目的:
- 为了评估65岁及以上的MCL患者的第一线治疗结果.
- 评估整体存活率 (OS) 和无进展存活率 (PFS).
- 为了确定影响这种患者队列生存的因素.
主要方法:
- 多中心回顾性研究,包括77名MCL患者 (≥65岁).
- 诱导化疗方案 (R-CHOP,RB,R-CVP,R-CHOP/R-DHA-白金),自身干细胞移植 (ASCT) 和Rituximab维护的分析.
- 评估整体反应率 (ORR),PFS,OS,以及预后因素的多变量分析.
主要成果:
- 中位数PFS为18个月,中位数OS为42个月.
- 劣质PFS的独立风险因素包括LDH升高,Ki67≥30%,布拉斯托异型,缺乏维持治疗.
- 劣质OS的独立风险因素包括缺乏维持治疗和POD24 (疾病在24个月内进展).
结论:
- 对于老年MCL患者来说,没有普遍接受的标准治疗方法.
- 升高的LDH,高的Ki67,布拉斯托类变体和POD24与较差的结果有关.
- 维护策略和向疗法在改善老年MCL患者的生存率方面表现有前途.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:21Cancer Survival Analysis
639
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
639